Peter Neupert serves as Interim Chief Executive Officer of Fortrea Holdings Inc., a global contract research organization (CRO) focused on accelerating drug development through clinical trial services. Appointed to this role in 2024 following Fortrea's spin-off from Laboratory Corporation of America Holdings (LabCorp), Neupert is steering the company through its transition to independence, emphasizing operational efficiency, innovation in clinical research, and client-centric solutions to advance biopharmaceutical pipelines worldwide. With more than 30 years in healthcare technology and services, Neupert's career highlights include his leadership at Cerner Corporation, where he served as President of the Global Business Division and Chief Strategy Officer. He played a pivotal role in expanding Cerner's international footprint, driving revenue growth to multi-billion-dollar levels, and pioneering health IT solutions that enhanced data interoperability and patient outcomes. Earlier, at Microsoft, Neupert led the Health Solutions Group, integrating cloud-based technologies with healthcare delivery to foster digital transformation. Neupert's achievements extend to advisory roles and board positions at organizations like the Gates Medical Research Institute and Invitae Corporation, where he championed precision medicine and genomic advancements. A recognized thought leader in digital health, he holds a proven track record of scaling enterprises and forging strategic partnerships, positioning Fortrea for sustained growth and leadership in the CRO industry.